Pharsight

Duaklir Pressair is owned by Astrazeneca.

Duaklir Pressair contains Aclidinium Bromide; Formoterol Fumarate.

Duaklir Pressair has a total of 5 drug patents out of which 1 drug patent has expired.

Expired drug patents of Duaklir Pressair are:

Duaklir Pressair was authorised for market use on 29 March, 2019.

Duaklir Pressair is available in powder, metered;inhalation dosage forms.

Duaklir Pressair can be used as maintenance treatment of chronic obstructive pulmonary disease (copd).

The generics of Duaklir Pressair are possible to be released after 13 March, 2029.

Application	Filing Date	Opposition Party	Legal Status
EP09719213A	2016-05-12	Generics (U.K.) Limited	Granted and Under Opposition
EP09719213A	2016-05-06	Hexal AG	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46417	ASTRAZENECA	Quinuclidine derivatives and their use as muscarinic M3 receptor ligands	Feb, 2025 (1 year, 8 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6681768	ASTRAZENECA	Powder formulation disintegrating system and method for dry powder inhalers	Aug, 2022 (9 months ago)
US8051851	ASTRAZENECA	Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler	Apr, 2027 (3 years from now)
US10085974	ASTRAZENECA	Dosage and formulation	Mar, 2029 (5 years from now)
US11000517	ASTRAZENECA	Dosage and formulation	Mar, 2029 (5 years from now)